Phase II trial of galactitol 1,2

5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: A gynecologic oncology group study

Frederick Stehman, Johannes Blom, John A. Blessing, Clarence E. Ehrlich, Charles Mangan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Dianhydrogalactitol was administered intravenously to patients with advanced or recurrent gynecologic malignancies on a weekly schedule. The initial dosage was 60 mg/m2 with escalation to 75 mg/m2 if there were no adverse effects. Forty-two patients with ovarian epithelial adenocarcinoma (OEA) and forty-one patients with squamous carcinoma of the cervix (SCC) were entered into this study. Of these, 39 patients with OEA and 36 with SCC were evaluable for toxicity and response. Seven patients (19.4%) with SCC had an objective response, while six patients (15.4%) with OEA had an objective response. Adverse effects were frequent but tolerable. There were no drug-related deaths, and only two patients suffered life-threatening hematologic toxicity. Myelosuppression was observed more frequently among the patients with OEA. A higher percentage of OEA patients had received prior chemotherapy. The level of activity and frequency of adverse effects observed at this dose schedule warrant further studies of this drug in these two tumors.

Original languageEnglish
Pages (from-to)381-390
Number of pages10
JournalGynecologic Oncology
Volume15
Issue number3
DOIs
StatePublished - 1983

Fingerprint

Dianhydrogalactitol
Adenocarcinoma
Neoplasms
Cervix Uteri
Squamous Cell Carcinoma
Therapeutics
Appointments and Schedules
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Phase II trial of galactitol 1,2 : 5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: A gynecologic oncology group study. / Stehman, Frederick; Blom, Johannes; Blessing, John A.; Ehrlich, Clarence E.; Mangan, Charles.

In: Gynecologic Oncology, Vol. 15, No. 3, 1983, p. 381-390.

Research output: Contribution to journalArticle

@article{df1e94b1a4f7492fbb5c2ec0544a7a1d,
title = "Phase II trial of galactitol 1,2: 5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: A gynecologic oncology group study",
abstract = "Dianhydrogalactitol was administered intravenously to patients with advanced or recurrent gynecologic malignancies on a weekly schedule. The initial dosage was 60 mg/m2 with escalation to 75 mg/m2 if there were no adverse effects. Forty-two patients with ovarian epithelial adenocarcinoma (OEA) and forty-one patients with squamous carcinoma of the cervix (SCC) were entered into this study. Of these, 39 patients with OEA and 36 with SCC were evaluable for toxicity and response. Seven patients (19.4{\%}) with SCC had an objective response, while six patients (15.4{\%}) with OEA had an objective response. Adverse effects were frequent but tolerable. There were no drug-related deaths, and only two patients suffered life-threatening hematologic toxicity. Myelosuppression was observed more frequently among the patients with OEA. A higher percentage of OEA patients had received prior chemotherapy. The level of activity and frequency of adverse effects observed at this dose schedule warrant further studies of this drug in these two tumors.",
author = "Frederick Stehman and Johannes Blom and Blessing, {John A.} and Ehrlich, {Clarence E.} and Charles Mangan",
year = "1983",
doi = "10.1016/0090-8258(83)90056-2",
language = "English",
volume = "15",
pages = "381--390",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Phase II trial of galactitol 1,2

T2 - 5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: A gynecologic oncology group study

AU - Stehman, Frederick

AU - Blom, Johannes

AU - Blessing, John A.

AU - Ehrlich, Clarence E.

AU - Mangan, Charles

PY - 1983

Y1 - 1983

N2 - Dianhydrogalactitol was administered intravenously to patients with advanced or recurrent gynecologic malignancies on a weekly schedule. The initial dosage was 60 mg/m2 with escalation to 75 mg/m2 if there were no adverse effects. Forty-two patients with ovarian epithelial adenocarcinoma (OEA) and forty-one patients with squamous carcinoma of the cervix (SCC) were entered into this study. Of these, 39 patients with OEA and 36 with SCC were evaluable for toxicity and response. Seven patients (19.4%) with SCC had an objective response, while six patients (15.4%) with OEA had an objective response. Adverse effects were frequent but tolerable. There were no drug-related deaths, and only two patients suffered life-threatening hematologic toxicity. Myelosuppression was observed more frequently among the patients with OEA. A higher percentage of OEA patients had received prior chemotherapy. The level of activity and frequency of adverse effects observed at this dose schedule warrant further studies of this drug in these two tumors.

AB - Dianhydrogalactitol was administered intravenously to patients with advanced or recurrent gynecologic malignancies on a weekly schedule. The initial dosage was 60 mg/m2 with escalation to 75 mg/m2 if there were no adverse effects. Forty-two patients with ovarian epithelial adenocarcinoma (OEA) and forty-one patients with squamous carcinoma of the cervix (SCC) were entered into this study. Of these, 39 patients with OEA and 36 with SCC were evaluable for toxicity and response. Seven patients (19.4%) with SCC had an objective response, while six patients (15.4%) with OEA had an objective response. Adverse effects were frequent but tolerable. There were no drug-related deaths, and only two patients suffered life-threatening hematologic toxicity. Myelosuppression was observed more frequently among the patients with OEA. A higher percentage of OEA patients had received prior chemotherapy. The level of activity and frequency of adverse effects observed at this dose schedule warrant further studies of this drug in these two tumors.

UR - http://www.scopus.com/inward/record.url?scp=0020639313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020639313&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(83)90056-2

DO - 10.1016/0090-8258(83)90056-2

M3 - Article

VL - 15

SP - 381

EP - 390

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -